Baxter International is collaborating with the FDA to address complaints raised in an agency warning letter regarding the marketing of Baxter's Isolex device used in cancer treatment, said company spokeswoman Mavis Prall. In its Sept. 10 letter, the agency warned the company that the product label was misleading.

Related Summaries